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Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from 
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy. Hence, 
there remains the need to develop new effective and well-tolerated therapies.
Aim: The objective of this article was to review the evidence for the efficacy and safety of 
eslicarbazepine acetate (ESL) as adjunctive treatment in adult patients with focal onset seizures.
Evidence review: ESL is the newest, third-generation, single enantiomer member of the 
dibenzazepine family. Following oral administration, ESL is rapidly and extensively metabolized 
by hepatic first-pass hydrolysis to the active metabolite eslicarbazepine, which has linear, dose-
proportional pharmacokinetics and low potential for drug-drug interactions. Eslicarbazepine 
works as a competitive blocker of the voltage gated sodium channels; unlike carbamazepine 
(CBZ) and oxcarbazepine (OXC), it has a lower affinity for the resting state of the channels, 
and reduces their availability by selectively enhancing slow inactivation. Efficacy and safety of 
ESL have been assessed in four randomized, Phase III clinical trials: the median relative reduc-
tion in standardized seizure frequency was 33.4% and 37.8% in the ESL 800 and 1,200 mg 
daily dose groups, and the responder rates were 33.8% and 43.1%, respectively. The incidence 
of treatment-emergent adverse events (TEAEs) increased with raising the dosage (ESL 400 
mg: 63.8%, ESL 800 mg: 67.0%, ESL 1,200 mg: 73.1%). The TEAEs were generally mild to 
moderate in intensity, and the most common were dizziness, somnolence, headache and nausea. 
Open-label studies confirmed the findings from the pivotal trials and demonstrated sustained 
therapeutic effect of ESL over time and improvement of tolerability profile in patients switching 
from OXC/CBZ. No unexpected safety signals emerged over >5 years of follow-up.
Conclusion: Once-daily adjunctive ESL at the doses of 800 and 1,200 mg was effective to 
reduce the seizure frequency and was fairly well tolerated in adults with focal onset epilepsy. 
Starting treatment at 400 mg/day, followed by 400 mg increments every 7–14 days, could provide 
the optimal balance of efficacy and tolerability.
Keywords: eslicarbazepine acetate, epilepsy, focal seizures, review
Clinical impact summary for eslicarbazepine acetate as adjunctive treatment in 
patients with focal onset seizures
Outcome measure Evidence Implications
Disease-oriented 
evidence
Seizure frequency 
reduction
Randomized, placebo-
controlled, double-
blind, clinical trials and 
observational, open-label 
studies
Once-daily eslicarbazepine acetate at the dosage 
of 800 and 1,200 mg consistently demonstrated 
to be effective in the adjunctive treatment 
of adult patients presenting with focal onset 
seizures. 
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Outcome measure Evidence Implications
A dose-dependent response occurred with an 
increase in effect by increasing the dose.
in the pooled analysis of the Phase iii pivotal 
trials, the median relative reduction in 
standardized seizure frequency was 33.4% and 
37.8% in the eslicarbazepine acetate 800 mg and 
1,200 mg daily dose groups and the responder 
rates were 33.8% and 43.1%, respectively. The 
drug efficacy was demonstrated regardless of 
whichever concomitant baseline, antiepileptic 
drugs were used.
Open-label studies showed similar results and 
demonstrated sustained therapeutic effect of 
eslicarbazepine acetate.
Patient-oriented 
evidence
Tolerability and safety Randomized, placebo-
controlled, double-
blind, clinical trials and 
observational, open-label 
studies
Once-daily eslicarbazepine acetate was well 
tolerated overall as adjunctive treatment in 
adults with focal onset epilepsy.
In the pooled analysis of the Phase III trials, 
the incidence of treatment-emergent adverse 
events increased with increase of the dose 
(eslicarbazepine acetate 400 mg: 63.8%, 
eslicarbazepine acetate 800 mg: 67.0%, 
eslicarbazepine acetate 1,200 mg: 73.1%); most 
of the treatment-emergent adverse events 
were mild to moderate in intensity. The most 
common were dizziness, somnolence, headache 
and nausea. The incidence of adverse events was 
higher in patients co-treated with carbamazepine 
than with other antiepileptic drugs.
Changes in mean laboratory parameters were 
not associated with clinically relevant findings, 
and there were no variations in vital signs, 
body weight or electrocardiography of clinical 
concern.
Hyponatremia leading to treatment 
discontinuation occurred in less than 1% of the 
patients taking eslicarbazepine acetate.
Similar results were observed in the open-label 
studies. Tolerability profile improved in patients 
switching from oxcarbazepine/carbamazepine to 
eslicarbazepine acetate due to side effects. No 
unexpected safety signals emerged over >5 years 
of follow-up.
Net benefit Randomized, placebo-
controlled, double-
blind, clinical trials and 
observational, open-label 
studies
Starting treatment at the 400 mg/day dose, 
followed by 400 mg increments every 7–14 days 
until the optimal dose is reached, can maximize 
the balance of efficacy and tolerability.
Economic 
evidence
Not available
Introduction
Epilepsy is one of the most common neurological disorders 
affecting approximately 70 million people worldwide. It has 
an annual incidence of about 80 cases per 100,000 people and 
a point prevalence between 4 and 10 cases per 1,000 people.1 
The treatment of epilepsy is mainly symptomatic and nearly 
70% of all patients have a good prognosis and achieve a long-
term remission. However, up to 30% of adults diagnosed with 
(Continued)
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epilepsy will continue suffering from seizures despite treat-
ment with antiepileptic drugs (AEDs), either in monotherapy 
or polytherapy.2 Notably, the inadequate seizure control, which 
may be related to either pharmacoresistance or intolerable 
adverse effects, is associated with physical risks and impair-
ments in social opportunities and has a negative influence 
on overall quality of life.3 Hence, there remains the need to 
develop new effective and well-tolerated treatment options.
Eslicarbazepine acetate (ESL) is a novel AED, which has 
been approved by the European Medicines Agency and the 
US Food & Drug Administration as monotherapy and adjunc-
tive therapy for focal onset seizures (FOS), with or without 
secondary generalization, in adults, and was recently autho-
rized also in children and adolescents as adjunctive treatment.
This paper provides a review of the available evidence 
on the efficacy and safety of ESL as adjunctive treatment in 
adult patients with FOS, and highlights major issues about 
its actual place in therapy.
Brief pharmacology: chemical structure, 
pharmacodynamics and pharmacokinetics
ESL is the newest, third-generation, single enantiomer 
member of the dibenzazepine family, which also includes 
carbamazepine (CBZ) (first generation) and oxcarbazepine 
(OXC) (second generation), and works as a competitive 
blocker of the voltage gated sodium channels (VGSC).4 The 
structural variation at the 10,11 position of the dibenzazepine 
nucleus conveys ESL unique pharmacodynamics and phar-
macokinetics.5 Compared to CBZ, ESL has similar affinity 
for the inactivated state and a threefold lower affinity for 
the resting state of the VGSC. Unlikely traditional sodium 
channel blockers, which interfere with the fast inactivation 
pathway, ESL reduces the VGSC availability by selectively 
enhancing slow inactivation, similarly to lacosamide.6,7 These 
properties result in stabilization of hyper-excitable neuronal 
membranes, inhibition of sustained repetitive production of 
action potentials characteristic of neurons involved in epi-
lepsy and reduction of long-term channel availability, with a 
low propensity to disturb physiological function.8
ESL is an oral pro-drug that is well absorbed following 
ingestion, with a bioavailability of approximately 94%, and 
is rapidly and extensively bio-transformed to its major active 
metabolite eslicarbazepine (S-licarbazepine) by hepatic first-
pass hydrolysis. Accordingly, plasma levels of ESL usually 
remain below the limit of quantification.9,10 The binding of esli-
carbazepine to plasma proteins is relatively low (<40%) and 
independent of concentration. Plasma peak dose is attained at 
2–3 hours post-dose, and the steady state levels are achieved 
after 4–5 days of once-daily dosing, consistent with an effec-
tive half-life of 20–24 hours.9,10 Minor metabolites in plasma 
include the right isomer of eslicarbazepine (R-licarbazepine) 
and OXC, which were shown to be active, and the glucuronic 
acid conjugates of ESL, S-licarbazepine, R-licarbazepine and 
OXC.9 The pharmacokinetics of ESL avoids the toxic product 
of CBZ degradation (i.e., carbamazepine-10,11-epoxide),4 and 
the early peak in plasma and cerebrospinal fluid (CSF) concen-
trations following immediate-release OXC administration.11 
Further, ESL does not affect its own metabolism or clearance; 
eslicarbazepine is a weak inducer of CYP3A4 and UDP-
glucuronyl transferases, and has inhibiting properties with 
respect to CYP2C19. ESL metabolites are eliminated from 
the systemic circulation primarily by renal excretion, in the 
unchanged and glucuronide conjugate forms; S-licarbazepine 
and its glucuronide correspond to more than 90% of total 
metabolites excreted in urine.9 Overall, the pharmacokinet-
ics of ESL are linear, dose-proportional in the 400–1,200 mg 
range and unaffected by age, sex and food intake.5,10,12
Drug formulation and dosing
ESL is an oral AED available in a liquid suspension or tablet 
form, which may be taken with or without food. The recom-
mended starting dose of ESL is 400 mg once daily, which 
should be increased to 800 mg once daily after 1 or 2 weeks; 
according to individual response, the dose as adjunctive 
treatment may be increased to 1,200 mg once daily.9 The 
plasma levels show a linear correlation with the posology, 
but a therapeutic range has not been defined.
Efficacy, tolerability and safety of 
adjunctive ESL in randomized, placebo 
controlled, double-blind trials
The adjunctive therapy program to evaluate the efficacy and 
tolerability of ESL in adult patients with FOS included one 
Phase II study (study BIA-2093-201)13 and four Phase III, 
multicenter, randomized, double-blind and placebo controlled 
clinical trials (studies BIA-2093-301 [NCT00957684], BIA-
2093-302 [NCT00957047], BIA-2093-303 [NCT00957372] 
and BIA-2093-304 [NCT00988429]).14–17 All the studies 
recruited patients presenting with at least four FOS per 
month, with or without secondary generalization, despite 
treatment with one to three AEDs at a stable dose; notably, 
OXC was not allowed as a concomitant AED as it has the 
same pharmacologically active main metabolite with ESL.
In the Phase II study,13 143 patients were randomized to 
treatment with ESL once daily, ESL twice daily, or placebo. 
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The ESL daily dose was gradually titrated up to 1,200 mg/day 
in three steps at 4-week intervals. A statistically significant 
difference from placebo in the response rate at the end of the 
12-week treatment period was found only for the once-daily 
group, whereas the incidence of adverse events was similar 
across the arms. Accordingly, ESL has been administered 
once a day in all the subsequent trials.
All the Phase III trials followed a similar design with 
ESL administered once daily for 12 weeks (maintenance 
period); the major differences in trial designs included the 
number of doses tested and the titration and tapering-off 
regimens. Studies BIA-2093-301 and BIA-2093-302 had 
three ESL daily dose groups (400, 800 and 1,200 mg),14,15 
whereas studies BIA-2093-303 and BIA-2093-304 had only 
two ESL doses (800 and 1,200 mg).16,17 In each of the indi-
vidual studies, the primary efficacy variable was the 4-week 
standardized seizure frequency (SSF) over the maintenance 
period, and the predefined key efficacy outcomes included 
the median reduction and the 50% or greater reduction in 
SSF (response rate) over the maintenance period compared 
to baseline. Safety assessment included treatment-emergent 
adverse events (TEAEs), clinical laboratory parameters, vital 
signs and electrocardiography. The main characteristics and 
results of the Phase III trials are summarized in the Table 1.
The population in the pivotal four trials was predomi-
nantly Caucasian with a mean age of 38 years and a mean 
disease duration of 22 years. The baseline seizure frequency 
was approximately 15 seizures/4 weeks, and all patients 
but five were taking at least one concomitant AED at the 
end of the baseline period. The most common concomitant 
drugs were CBZ, lamotrigine and valproic acid.18 Overall, 
results of these studies clearly demonstrated that once-daily 
ESL at the dosage of 800 or 1,200 mg is effective and well 
tolerated as adjunctive treatment in patients with focal onset 
epilepsy; furthermore, starting treatment at the 400 mg/day 
dose, followed by 400 mg increments, provides optimal bal-
ance of efficacy and tolerability.18 In a pooled analysis of the 
integrated datasets, the median relative reduction in SSF was 
17.6% in the placebo group compared to 23.4%, 33.4% and 
37.8% in the ESL 400, 800 and 1,200 mg groups, respec-
tively; the responder rates were 22.9%, 33.8% and 43.1% for 
the ESL 400, 800 and 1,200 mg daily doses, respectively, and 
22.2% for the placebo group.18 The differences to placebo 
were statistically significant only for the ESL 800 and 1,200 
mg doses; the drug efficacy was demonstrated regardless of 
whichever concomitant baseline AEDs were used. The over-
all incidence of TEAEs increased with the increase of ESL 
dose (ESL 400 mg: 63.8%, ESL 800 mg: 67.0%, ESL 1,200 
mg: 73.1%; placebo: 52.7%); this trend was also observed 
for TEAEs leading to drug withdrawal (ESL 400 mg: 8.7%, 
ESL 800 mg: 12.2%, ESL 1,200 mg: 22.2%; placebo: 6.2%); 
mainly dizziness and nausea.18 The most common TEAEs, 
reported by at least 10% of the patients, were dizziness, 
somnolence, headache and nausea; notably, the incidence 
of adverse events was higher in patients co-treated with 
CBZ than with other AEDs. A shift of sodium levels from 
Table 1 Main characteristics and results of the Phase III, randomized, double-blind, placebo-controlled trials of adjunctive eslicarbazepine 
acetate in patients with refractory focal onset seizures
Study 
(reference)
AEDs 
allowed
Titration Tapering-off Treatment 
arms
Median relative 
reduction in SSF
Reduction in 
SSF ≥50%
Any 
TEAEs
BiA-2093-30114 1–2 At 400 mg weekly 
steps
At 400 mg weekly 
steps until 0 mg 
(PBO)
N=402  
PBO=102  
ESL 400 mg=100 
ESL 800 mg=98 
ESL 1,200 mg=102
16.0% 
26.0% 
36.0% (p<0.05) 
45.0% (p<0.001)
20.0% 
23.0% 
34.0% (p<0.05) 
43.0% (p<0.001)
31.4% 
44.0% 
50.0% 
60.8%
BiA-2093-30215 1–3 No titration in the 
400 and 800 mg arms; 
starting with 800 mg 
in the 1,200 mg arm
No tapering-off N=395  
PBO=100  
ESL 400 mg=96 
ESL 800 mg=101 
ESL 1,200 mg=98
0.8%  
18.7% 3 
2.6% (p<0.001) 
32.8% (p<0.001)
13.0%  
16.7%  
40.0% (p<0.001) 
37.1% (p<0.01)
68.0% 
78.1% 
83.2% 
79.6%
BiA-2093-30316 1–2 Starting with half 
of the assigned 
maintenance dose
At 2 weeks: half of 
the maintenance 
dose; at 2 weeks: 
0 mg (PBO)
N=252  
PBO=87  
ESL 800 mg=85 
ESL 1,200 mg=80
17.0%  
37.9% (p<0.05) 
41.9% (p<0.05)
22.6  
34.5  
37.7 (p<0.05)
39.1% 
52.9% 
61.3%
BiA-2093-30417 1–2 At 400 mg weekly 
steps
At 400 mg weekly 
steps until 400 mg
N=650  
PBO=224  
ESL 800 mg=216 
ESL 1,200 mg=210
21.8%  
29.7%  
35.6% (p<0.05)
23.1%  
30.5%  
42.6% (p<0.001)
55.8% 
67.1% 
77.6%
Abbreviations: AED, antiepileptic drug; PBO, placebo; ESL, eslicarbazepine acetate; SSF, standardized seizure frequency; TEAEs, treatment-emergent adverse events.
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normal at baseline to low (i.e., <135 mEq/L) at the end of the 
maintenance treatment phase was found in 1.8% of patients 
treated with placebo, and in 6.1%, 4.8% and 6.6% of patients 
treated with ESL 400, 800 and 1,200 mg daily, respectively; 
hyponatremia leading to treatment discontinuation occurred 
in less than 1% of the patients taking ESL.18
The incidence of TEAEs was lower in patients who initi-
ated ESL at 400 mg/day, followed by 400 mg increments, than 
in those starting treatment at higher dosages.18 Changes in 
mean laboratory parameters were not associated with clini-
cally relevant findings, and there were no variations in vital 
signs, body weight or electrocardiography of clinical concern.
Open-label extension and real-world 
studies
Two 1-year, open-label extension studies19,20 including 
patients who completed the randomized pivotal Phase III 
trials14,15 were performed. The starting ESL daily dose was 
800 mg, which could be individualized thereafter within 
the 400–1,200 mg range, while keeping stable the dosages 
of concomitant AEDs. Overall, these studies demonstrated 
Table 2 Summary of the real-world studies of adjunctive eslicarbazepine acetate in focal onset seizures
Study Study design Patient characteristics Main outcome measures Authors’ conclusion
Euro-Esli21 Pooled analysis 
of 14 European, 
prospective and 
retrospective 
clinical audit 
studies*
N=2,058
Male: 52.1%
Age: 44.0 (15) years
Epilepsy duration: 20.9 (16.4) years
Baseline monthly seizure 
frequency: 13.6 (49.9)
Number of concomitant AEDs: 
1.7 (1.0)
Retention rate: 73.4% (12 months)
Responder rate: 75.6% (12 months)
Seizure freedom: 41.3% (12 months)
AEs: 34.0%
Discontinuation due to AEs: 13.6%
Most frequent AEs: dizziness (6.7%), 
fatigue (5.4%), somnolence (5.1%)
ESL more effective in patients aged ≥65 
years, not receiving treatment with other 
sodium channel blockers, receiving <2 
concomitant AEDs
Euro-Esli is the largest ESL 
clinical practice study available 
to date.
it provides strong and 
reassuring evidence of ESL’s 
safety profile. No unexpected 
safety signals emerged over a 
median duration of follow-up 
of >5 years.
ESLADOBA22 Prospective, 
multicenter 
(Portugal); ESL as 
add-on therapy to 
one AED
N=52
Male: 48.1%
Age: 41.5 (13.3) years
Epilepsy duration: 18.5 (14.8) years
Baseline monthly seizure 
frequency: 7.5 (12.7)
Retention rate: 73.0% (6–9 months)
Responder rate: 71.1% (6–9 months)
Seizure freedom: 39.5% (months)
AEs: 23.1%
Discontinuation due to AEs: 9.6%
Reduction in Clinical Global impression 
of Severity: 42.1%
ESL showed good retention 
rates, elicited a significant 
reduction in seizure frequency 
and was well tolerated when 
used in clinical practice.
EARLY-ESLi23 Retrospective, 
multicenter 
(Spain), 1-year 
observational; ESL 
as add-on after 
first monotherapy 
failure
N=253
Male: 57.3%
Age: 48.7 (18–87) years
Epilepsy duration: 3 (1–10) years
Baseline monthly seizure 
frequency: 2.9 (16.1)
Final median ESL dose: 800 mg/day
Retention rate: 92.9% (12 months)
Responder rate: 70.5% (3 months), 79.8% 
(6 months), 82.5% (12 months)
Seizure freedom: 37.3% (12 months)
AEs: 31.6%
Discontinuation due to AEs: 3.6%
Most common AEs: somnolence (8.7%), 
dizziness (5.1%).
After starting ESL, 54.2% patients 
withdrew the prior monotherapy and 
converted to ESL alone
The administration of ESL 
after the first monotherapy 
failure was associated with an 
optimal seizure control and 
tolerability profile. Over half 
of the patients were converted 
to ESL monotherapy during 
follow-up.
sustained therapeutic effect and favorable long-term safety 
and tolerability of once-daily adjunctive ESL. A total of 462 
patients concluded the 1year of treatment; compared to the 
baseline period of the corresponding double-blind trial, the 
median seizure frequency decreased by 32–39% in weeks 
1–4, and between 37% and 56% thereafter. The responder 
rate was 37–41% during the first 4 weeks, and then ranged 
from 38% to 53% per 12-week interval. The proportion of 
seizure-free patients per 12-week interval ranged between 
5.0% and 12.5%. Adverse events were reported by 51–83% 
of the patients; the most common adverse events were dizzi-
ness and headache and they were usually of mild to moderate 
intensity. Significant improvements in quality of life domains 
and depressive symptoms were also observed.
Different prospective and retrospective real-world studies 
have been performed after ESL’s authorization as adjunctive 
treatment in FOS:21–30 they have provided reassuring evidence 
of its efficacy and safety in routine clinical care and across 
different baseline patient conditions, and have complemented 
data from clinical trials. The characteristics and findings of 
the main real-life studies are summarized in Table 2.
(Continued)
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Study Study design Patient characteristics Main outcome measures Authors’ conclusion
EPOS24–26 Prospective, 
multicenter 
(Europe); ESL as 
add-on therapy to 
one AED
N=219
Male: 57.5%
Age: 43 (18–83) years
Epilepsy duration: 12.3 (0–57.3) 
years
Seizure frequency over 3 baseline 
months: 29.3 (95.8).
Non-responder to CBZ: N=45.
Age: >60 yrs
N=41
ESL 800 mg/day: 74.3%.
Target dose achieved with one 
titration step: 79.3%.
Retention rate: 89.0% (3 months), 
82.2% (6 months)
Responder rate: 69.9% (3 months), 
81.8% (6 months)
Seizure freedom: 25.9% (3 months), 
39.2% (6 months)
AEs: 26.0%
Discontinuation due to AEs: 11.4%
Most frequent AEs: dizziness (4.6%), 
headache (3.2%), convulsion (3.2%), 
fatigue (2.7%)
Decrease (i.e., improvement) of 
QOLiE-10 from 2.9 (baseline) to 2.4 
(3 months) and 2.1 (6 months)
Adjunctive ESL therapy to 
one AED showed favorable 
retention, seizure control and 
tolerability, and improvement 
in quality of life.
ESL in patients less refractory 
than those included in clinical 
trials led to higher responder 
and seizure freedom rates.
ESL was effective and generally 
well tolerated in elderly 
patients and in those who had 
previously not responded to 
CBZ therapy.
Correia et al27 Retrospective, 
single-center 
(Portugal), 2-year 
observational
N=152
Male: 50.6%
Age: 38.5 (14.2) years
Epilepsy duration: 26.8 (13.1) years
Baseline monthly seizure 
frequency: 19.7 (32.9).
Two or more AEDs at baseline: 
57.9%
Retention rate: 82.9% (6 months), 
71.3% (12 months), 65.1% (18 months), 
62.8% (24 months)
Responder rate: 25.7% (6 months), 
25.7% (12 months), 19.0% (18 months), 
17.1% (24 months)
AEs: 42.1%
Discontinuation due to AEs: 21.1%
Most frequent AEs: dizziness, somnolence
AEs more common in regimens with CBZ
ESL appears to be a clinically 
useful add-on AED, with 
good safety profile and high 
retention rates throughout 
2 years, even in a very 
refractory group of patients.
ESLiBASE28 Retrospective, 
multicenter (Spain), 
non-interventional
N=327
Male: 48.0%.
Age: 41.9 (14–87) years
Two or more AEDs at baseline: 
78%
Median ESL daily dose: 800 mg 
(3 months), 1,200 mg (6 and 
12 months)
Retention rate: 89.3% (3 months), 80.1% 
(6 months), 72.5% (12 months)
Responder rate: 46.3% (3 months), 57.9% 
(6 months), 52.5% (12 months)
Seizure freedom: 21.0% (3 months), 
28.0% (6 months), 25.3% (12 months)
AEs: 40.7% (12 months)
Discontinuation due to AEs: 16.2% 
(12 months)
Most common AEs: dizziness/nausea 
(11.3%), somnolence (6.1%), ataxia (5.1%)
ESL was well tolerated and 
effective over 1 year. The 
responder rate increased 
when ESL was combined 
with a non-sodium channel-
targeting drug.
Tolerability profile improved in 
>50% of the patients switching 
from OXC/CBZ to ESL due 
to AEs.
Massot et al29 Observational, 
single-center 
(Spain), descriptive, 
cross-sectional
N=61
Male: 31.5%
Age: 43.6 (14.4) years
Baseline monthly seizure 
frequency: 5.5 (1.13–30).
ESL 800 mg/day: 42.6%.
Mean follow-up duration: 4.7 
(3.2) months
Retention rate: 75.4% (3 months)
Reduction of monthly median seizure 
frequency by 63.6%
AEs: 57.4%
Most common AE: dizziness (34.4%)
Twelve patients (19.7%) switched 
overnight to ESL from OXC (ratio 
1:1), and 13 patients (21.3%) switched 
overnight from CBZ to ESL (ratio 1:1.3). 
At 3 months after the transition, median 
frequency decreased by 20%.
ESL is effective in the 
treatment of focal epilepsies 
and its early retention rate is 
>70%.
AEs mostly occurred during 
the titration phase.
Serrano-
Castro et al30
Observational 
single-center 
(Spain)
N=105
Male: 51.4%
Responder rate: 58.4% (6 months)
Seizure freedom: 20.7% (6 months)
AEs: 18.1% (6 months)
Most common AE: cognitive disorders.
Treatment discontinuation: 11.5%.
ESL is well tolerated and 
effective as an add-on therapy 
with most of the AEDs. 
Add-on to lacosamide was 
less effective; association 
with other sodium channel 
inhibitors had similar efficacy 
than others combinations with 
other AEDs.
Notes: *Including the ESLADOBA, Early-Esli, EPOS, Correia et al, ESLIBASE and Massot et al studies. Data are presented as mean (standard deviation) or median 
(interquartile range).
Abbreviations: AE, adverse event; AED, antiepileptic drug; CBZ, carbamazepine; ESL, eslicarbazepine acetate; OXC, oxcarbazepine; QOLIE-10, Quality of Life in Epilepsy 
inventory-10.
Table 2 (Continued)
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Clinical use
Renal and hepatic impairment
ESL metabolites are eliminated from the systemic circulation 
primarily by renal excretion, and clearance is dependent on 
kidney function in patients with mild to severe renal impair-
ment. Dose adjustment is not required if creatinine clearance 
(CrCl) is >60 mL/min; in patients with CrCl between 30 and 
60 mL/min, the initial ESL dose should be 200 mg once daily 
or 400 mg every other day for 2 weeks, followed by a once-
daily dose of 400 mg, which may be increased up to 600 mg/
day on the basis of individual response. ESL is not recom-
mended in patients with severe renal impairment (CrCl<30 
mL/min) due to insufficient data. Hemodialysis partially 
removes ESL and its metabolites from plasma. The liver 
function has less critical effects on the pharmacokinetics of 
ESL, and patients with mild to moderate hepatic impairment 
do not need dosage adjustment. Conversely, the drug has not 
been evaluated in the presence of severe liver dysfunction, 
and its use is not recommended in this setting.9
Drug interactions
An increase in the dose of the medicinal products that are 
mainly metabolized through CYP3A4 (e.g., simvastatin) 
or eliminated by conjugation through the UDP-glucuronyl 
transferases may be required when co-administered with ESL 
due to its inducer effect, albeit weaker than CBZ. Eslicar-
bazepine has inhibiting properties with respect to CYP2C19, 
and interactions can arise when ESL is taken with drugs that 
are substrates of this enzyme (e.g., diazepam).
Oral anticoagulants and digoxin
ESL at the 1,200 mg daily dose decreases plasma exposure 
to S-warfarin by 23%, without significant effects on the 
R-warfarin pharmacokinetics or coagulation: due to inter-
individual variability in the interaction, it is, however, advis-
able to carefully monitor the international normalized ratio 
during the first weeks after initiation or ending concomitant 
treatment of warfarin and ESL. No studies have specifically 
assessed whether pharmacological interactions exist between 
ESL and the direct oral anticoagulants. No influence of ESL 
on digoxin pharmacokinetics has been observed, suggest-
ing the lack of meaningful interactions with the transporter 
P-glycoprotein.9
Antiepileptic drugs
The co-administration of ESL and CBZ results in an average 
decrease of 32% in exposure to eslicarbazepine, most likely 
caused by an induction of glucuronidation; this may require 
an increase of ESL dose. Remarkably, the concomitant treat-
ment with ESL and CBZ can increase the risk to develop 
diplopia, abnormal coordination and dizziness.
The concomitant use of ESL and phenytoin determines 
a reduction of one-third in exposure to the active metabolite 
eslicarbazepine, due to an induction of glucuronidation, and 
an increase of 31–35% in exposure to phenytoin, caused by 
CYP2C19 inhibition. Accordingly, based upon individual 
response, the dose of ESL may need to be increased and the 
dose of phenytoin to be decreased.
Data from healthy subjects revealed minor pharmaco-
kinetic interactions between ESL and lamotrigine (15% 
decrease in exposure to lamotrigine) or topiramate (18% 
decrease in exposure to topiramate). ESL does not appear to 
interact significantly with levetiracetam and valproate.9 Nota-
bly, concomitant use of ESL with OXC is not recommended 
since it may cause overexposure to the active metabolites.
Oral contraceptives
Eslicarbazepine may decrease the effectiveness of hormonal 
contraception: the administration of ESL (1,200 mg/day) to 
female subjects using combined oral contraceptives showed 
an average decrease in systemic exposure to levonorgestrel 
of 37% and to ethinylestradiol of 42% owing to the CYP3A4 
induction. Therefore, to avoid inadvertent pregnancy, women 
of childbearing potential may need an increase in oral con-
traceptive dose or use alternative methods of contraception 
during ESL treatment and up to the end of the current men-
strual cycle after treatment has been stopped.9
Fertility, pregnancy and lactation
Epilepsy is a common neurologic disorder and the majority 
of affected people are expected to participate fully in life 
experiences, including childbearing. The prevalence of epi-
lepsy among pregnant women is up to 0.7%, and from three 
to five births per thousand will be to women with epilepsy.31,32 
Worldwide registries and observational studies have provided 
consistent findings on the risks related to both epilepsy itself 
and many of the older antiepileptic medicinal products, while 
there remains a large gap in the knowledge of most of the 
newer ones, including ESL.33 In studies in mice, impairment 
of fertility has been shown after treatment with ESL, like 
a decrease in implantations and live embryos. ESL has no 
teratogenic effects in the rat or rabbit, but induced skeletal 
abnormalities in the mouse. Ossification delays, reduced fetal 
weights, increases in minor skeletal and visceral anomalies 
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were observed at maternal toxic doses in embryo-toxicity 
studies in mice, rats and rabbits.9 Additionally, animal studies 
have shown excretion of eslicarbazepine in breast milk. To 
date, there are insufficient data to allow conclusions about the 
safety of ESL in pregnant women, and it is unknown whether 
it is excreted in human milk. Accordingly, specialist advice 
should be given to women who become or plan to become 
pregnant while receiving ESL.
Elderly population (over 65 years of age)
A post-approval commitment, multicenter, open-label, non-
controlled, single-arm study (BIA-2093-401 [NCT01422720]) 
with flexible dose of ESL between 400 and 1,200 mg daily 
was performed to address the safety and efficacy of ESL as 
adjunctive treatment in the elderly. Among 72 patients treated 
with one or two concomitant AEDs, the ESL dose did not 
exceed 800 mg/day in the majority of the cases. The treatment 
was associated with a 54% relative reduction in the stan-
dardized baseline seizure frequency and did not raise major 
safety concerns. The overall frequency of TEAEs (65.3%) 
was similar to the rate observed in the pooled Phase III 
studies, and the most common were dizziness (12.5%) and 
somnolence (9.7%); notably, the incidence of hyponatremia 
(8.3%) was slightly higher than the proportion observed in 
the randomized clinical trials. Overall, 25% of the subjects 
discontinued prematurely due to side effects.34
A retrospective survey that included elderly patients 
with focal seizures who started ESL in 12 Spanish hospi-
tals, according to real-life experience between 2010 and 
2012, was reported as part of the ESLIBASE study. In all, 
29 patients with a mean age of 71.2 years were included, 
of whom 18 were pharmacoresistant. At 1 year, the mean 
ESL daily dose was 850 mg and the retention rate was 69%. 
Sixty-two percent of the patients were seizure responders, 
and 24.1% were free from seizures. Adverse effects were 
experienced by 55.2% of the study cohort and led to treat-
ment discontinuation in seven (24.1%) cases. The most 
common side effects were dizziness, nausea and ataxia; the 
tolerability profile improved in most of the patients who 
switched from CBZ or OXC to ESL.35 In a single-center, 
retrospective study of patients treated with ESL, there was 
no significant difference in the prevalence of mild adverse 
effects between young and elderly (≥60 years old) adults, 
whereas adverse effects leading to treatment discontinua-
tion were more frequent in the elderly group.36 Notably, the 
pharmacokinetic profile of ESL is unaffected in the elderly 
and no dose adjustment is needed, provided that renal func-
tion is preserved (CrCl >60 mL/min).9
Transitioning from OXC or CBZ to ESL
The switch from OXC to ESL is easy to perform: a dose 
ratio of 1:1 should be employed to estimate the ESL target 
dose, transition can take place overnight and no changes to 
co-medication are required.37 Conversely, the change from 
CBZ to ESL is less straightforward and requires careful 
considerations on a patient-by-patient basis: a dose ratio of 
1:1.3 should be considered, the conversion period should last 
a minimum of 1–2 weeks, although longer intervals may be 
advised, and concomitant medications metabolized by cyto-
chrome enzymes may require dose adjustment.37
Transition to ESL might be appropriate in patients who 
experience or are at risk to develop CBZ- or OXC-related 
adverse events, including metabolic disorders resulting from 
enzyme induction like hypercholesterolemia, osteoporosis 
or sexual dysfunction, in patients who are poorly compli-
ant with two- or three-daily dosing regimen, frequently 
forget to take their medication or work rotating shifts, and 
in patients who are poly-medicated or affected by cognitive 
dysfunction or liver disease.37,38 Notably, epilepsy is common 
among patients with cognitive impairment and dementia,39 
and the good profile of ESL with respect to neurocognitive 
functioning can make it a preferable option over AEDs, like 
CBZ, characterized by deeper effects on psychomotor per-
formance.40,41 In this regard, a recent network meta-analysis 
has compared the tolerability of the new-generation sodium 
blocker AEDs in drug-resistant epilepsies from double-
blind, placebo-controlled trials. At the highest recommended 
doses, treatment withdrawal was more frequently observed 
in patients treated with OXC than with ESL and lacosamide, 
and vestibulocerebellar side effects including abnormal 
coordination, ataxia and diplopia were more common among 
patients taking OXC rather than ESL.42
Overall, ESL has been shown to be less frequently asso-
ciated with cutaneous reactions in comparison to CBZ, and 
the lack of a toxic epoxide derivative could reduce the risk 
of developing rash.10 In patients known to be positive for 
HLA-B*1502 or HLA-A*3101, medications other than CBZ 
should be used and, due to possible cross-reactivity, CBZ-
related compounds such as OXC should also be avoided.43 In 
this respect, the official summary of product characteristics 
contraindicates ESL in patients with hypersensitivity reac-
tions to CBZ.9 A recent report described the case of a patient 
with the HLA-A*31:01 haplotype who, after the development 
of a severe cutaneous reaction following CBZ administration, 
was successfully prescribed ESL without experiencing any 
adverse event,44 and it suggested that ESL may be considered 
if the benefits are thought to exceed the risks. The safety of 
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ESL in subjects with HLA-B*15:02 or HLA-A*31:01 haplo-
types and a history of CBZ- or OXC-induced hypersensitivity 
reactions remain, however, to be fully addressed in larger 
studies before drawing definitive conclusions.
The overnight OXC-ESL transition resulted in improve-
ments in side effects, quality of life and alertness, while 
maintaining seizure control.45,46 In addition, compared with 
the first- and second-generation dibenzazepine as well as 
the traditional inducer AEDs, ESL may be preferred in 
patients at higher vascular risk47,48 by exhibiting a safer 
profile according to lipid metabolism and atherosclerosis 
development.49–51
Apart from the selective interaction with the inactive 
state of the VGSC and the reduction of their availability by 
interfering with the slow inactivation pathway, distinctive 
properties of ESL include the blockade of high- and low-
affinity hCaV3.2 inward currents with a 10–60-fold higher 
potency than CBZ, the lack of effect upon KV7.2 outward 
currents and the block of T-type CaV3.2 channels. Moreover, 
while CBZ and OXC show pro-epileptic actions at clinically 
relevant concentrations through the enhancement of the 
excitatory post-synaptic transmission, ESL has no effects 
on post-synaptic currents, explaining its lack of seizure 
exacerbation.52,53 ESL may not only suppress seizure activity, 
but also inhibit the generation of a hyperexcitable network, 
and it can overcome cellular mechanisms of resistance to 
sodium-channel acting AEDs.52,54 In this respect, a real-world 
clinical experience has suggested that ESL may represent an 
effective therapeutic option even in those patients who have 
previously tried, but discontinued the older carboxamides, 
regardless of the reasons for discontinuation.55
Conclusion
Once-daily ESL at the doses of 800 and 1,200 mg showed 
consistent results across efficacy and safety endpoints both in 
randomized-controlled and open-label studies. Notably, start-
ing treatment at 400 mg/day, followed by 400 mg increments 
every 7–14 days up to the optimal dose, could maximize the 
balance between seizure control and tolerability.18
Despite the lack of direct comparisons, the distinctive 
chemical structure of ESL compared to the older members 
of the dibenzazepine family, CBZ and OXC, can convey it 
unique advantages, including the once-daily regimen, the 
lower potential for drug-drug interactions and the more 
favorable tolerability profile, while enjoying similar efficacy. 
Additionally, ESL has shown the potential to be effective 
in syndromes characterized by high refractoriness to drug 
treatment, like the mesial temporal lobe epilepsy associated 
with hippocampal sclerosis.56
In conclusion, ESL represents an interesting improvement 
on a classic drug family for the treatment of FOS, and it has 
the potential to enhance the quality of life for drug-refractory 
patients.57
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